February 17th 2025
“Over 80% of patients…had at least 2 lines of therapy, so this is a heavily refractory population,” said Toni K. Choueiri, MD, FASCO.
Sunitinib vs. everolimus: PFS, toxicity differ in study
April 4th 2016In a head-to-head comparison, sunitinib (Sutent) prolonged radiographic progression-free survival compared with everolimus (Afinitor), but with greater toxicity, in patients with specific subtypes of metastatic renal cell carcinoma and non-clear cell histology, said Andrew J. Armstrong, MD, MSc.
Uro Pipeline: 1st patients treated in phase III study of investigational BPH Tx
January 1st 2016Other pipeline products discussed in this article include an immunotherapy for metastatic bladder cancer, a treatment for lower urinary tract symptoms of BPH, and an investigational clear cell renal cell carcinoma treatment.
Study appears to refute obesity paradox in kidney cancer
December 9th 2015In this interview Mark A. Preston, MD, MPH, of Brigham and Women’s hospital sat down with Richard. R. Kerr, Urology Times content channel director, to discuss the association between obesity and incidence of total and fatal renal cell carcinoma in two prospective cohorts. The interview was conducted during the AUA annual meeting in New Orleans.
Robot linked with improved kidney Ca care
December 15th 2014Kidney cancer patients were more likely to undergo partial nephrectomy when treated in hospitals that were early adopters of robotic surgery, according to a recent report that one leading expert calls “some of the best evidence to date of a favorable impact of surgical robots in urologic care.”
Laparoscopy/robotics studies explore the limits of minimally invasive surgery
April 17th 2014Urologists continue to push the limits of minimally invasive surgery, and key papers presented at the AUA meeting will explore the functional and cancer control outcomes associated with minimally invasive and robotic procedures in prostate cancer and renal cell carcinoma. When to use such approaches remains a source of controversy.
Urology Product Preview April 2014
April 16th 2014Drugs and devices in the pipeline from Astellas Pharma, Medivation, Repros Therapeutics, Metamark Genetics, Argos Therapeutics, S1 Biopharma, Ipsen, Sprout Pharmaceuticals, Antigen Express, Generex Biotechnology, Veloxis Pharmaceuticals, and Absorption Pharmaceuticals.
‘Obesity paradox’ appears to fit for men with renal cell carcinoma
April 10th 2014A study from Memorial Sloan-Kettering Cancer Center, New York sheds light on the “obesity paradox” seen with renal cell carcinoma while at the same time demonstrating the emerging value of genomics in understanding cancer and other diseases.
Sequential therapies for metastatic renal cell carcinoma yield similar results
March 21st 2014The sequential use of two targeted treatments for metastatic renal cell carcinoma appears to yield similar total progression-free survival regardless of the order in which they are given, phase III study results indicate.
Study may signify shift in RCC standard of care
August 23rd 2013The tyrosine kinase inhibitors pazopanib (Votrient) and sunitinib (Sutent) had similar benefits in delaying progression of advanced renal cell carcinoma, but the safety profile and many measures of quality of life favored pazopanib, according to data from a recently published multicenter study.
Response letter received regarding new drug application for kidney cancer agent
June 17th 2013AVEO Oncology recently announced that it has received a complete response letter from the FDA informing the company that the FDA will not approve in its present form the new drug application for AVEO’s investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.